The Centre for Blood Transplant and Cell Therapies (CBTCT) brings together the largest allogeneic stem cell transplant units in Australia with a focus on identifying transplant and cell therapy strategies to reduce graft versus host disease and improve patient and disease outcomes after transplant.
In this webinar series, investigators from the CBTCT will review major topics in stem cell transplantation and cell therapy, highlighting how the activities of the CBTCT are addressing current challenges in stem cell transplantation.
The final seminar of the 2020 CBTCT webinar series features Professor David Curtis reviewing the significance and potential management approaches to minimal residual disease in the peri-allogeneic blood transplant setting, followed by Professor David Ritchie highlighting the importance of the cellular therapies laboratory with the emergence of commercially available chimeric antigen receptor (CAR) T cell therapies.
Professor David Curtis – The Alfred Hospital and Monash University
Professor David Ritchie – Royal Melbourne Hospital and the University of Melbourne
When: Monday 26 October 2020, 12pm AEDT
Link to webinar:
Link to CBTCT website for all webinar recordings:
Haematology Society of Australia and New Zealand (HSANZ)
145 Macquarie Street, Sydney NSW 2000
Tel: 02 8097 8114
Copyright © 2020 Haematology Society of Australia & New Zealand (HSANZ). All Rights Reserved.